10-Q: Twist Bioscience Reports 28% Revenue Growth in Q3 2024, Despite Increased Net Losses

Twist Bioscience saw a 28% increase in revenue in the third quarter of 2024, driven by strong growth in NGS tools and synthetic genes, but also experienced a significant increase in net losses due to impairment charges.

Summary

• Twist Bioscience reported a 28% increase in revenue for the third quarter of 2024, reaching $81.5 million, compared to $63.7 million in the same period last year.
• The revenue growth was primarily driven by increased sales of NGS tools and synthetic genes, including the Express Genes product line.
• The number of genes shipped increased by 24% to 212,000 in Q3 2024, compared to 171,000 in Q3 2023.
• Gross margin improved to 43.3% in Q3 2024, up from 34.4% in Q3 2023.
• However, the company's net loss widened to $85.6 million in Q3 2024, compared to a net loss of $57.4 million in Q3 2023.
• This increase in net loss was largely due to a $44.9 million impairment charge related to the Biopharma asset group.
• For the nine months ended June 30, 2024, revenue reached $228.3 million, a 28% increase compared to $178.2 million in the same period last year.
• The net loss for the nine months ended June 30, 2024 was $174.1 million, compared to $158.4 million for the same period in 2023.
• The company's cash and cash equivalents and short-term investments totaled $289.4 million as of June 30, 2024.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While revenue growth is strong and gross margins improved, the significant increase in net loss due to impairment charges and rising operating expenses raises concerns. The material weakness in internal controls also contributes to a negative sentiment.

Positives

• Revenue increased by 28% year-over-year, indicating strong demand for Twist Bioscience's products.
• Gross margin improved significantly, suggesting better cost management and pricing strategies.
• The number of genes shipped increased by 24%, demonstrating increased production and sales volume.
• Net cash used in operating activities decreased substantially, indicating improved operational efficiency.

Negatives

• The company's net loss increased significantly, primarily due to a large impairment charge.
• The impairment charge of $44.9 million indicates a potential overvaluation of the Biopharma asset group.
• Operating expenses, particularly selling, general, and administrative costs, increased by 23% in Q3 2024.

Risks

• The company's ability to achieve profitability depends on the success of its existing products and the development of new products.
• The company faces risks related to market acceptance of its products, competition, and the ability to manage growth.
• The company has a history of net losses and may not achieve profitability in the near future.
• The company's internal controls over financial reporting have been identified as having a material weakness.
• The company is subject to ongoing legal proceedings, including a securities class action lawsuit.

Future Outlook

The company expects to continue investing in product development, manufacturing, and sales and marketing, and anticipates continued losses as it works towards profitability. The company believes its current cash and cash equivalents and short-term investments will be sufficient to fund operations for at least one year from the issuance of these financial statements.

Management Comments

• Management believes that the company's cash and cash equivalents and short-term investments will be sufficient to fund operations for at least one year from the issuance of these consolidated financial statements.
• Management intends to vigorously defend themselves against the claims asserted against them in the securities class action lawsuit.

Industry Context

The synthetic biology and genomics industry is experiencing rapid growth, with increasing demand for DNA synthesis and related products. Twist Bioscience is positioned to capitalize on this growth with its unique technology platform, but faces competition from other players in the market. The company's focus on expanding its product offerings and international presence aligns with industry trends.

Comparison to Industry Standards

• Twist Bioscience's revenue growth of 28% is strong compared to some of its peers in the synthetic biology space, but the significant net loss and impairment charges are concerning.
• Companies like Ginkgo Bioworks and Amyris also operate in the synthetic biology sector, but their financial performance and business models differ significantly.
• Ginkgo Bioworks, for example, focuses on platform development and partnerships, while Amyris has a broader portfolio including consumer products.
• Twist's gross margin improvement to 43.3% is a positive sign, but it needs to be sustained and improved further to achieve profitability.
• The impairment charge of $44.9 million is a significant deviation from industry norms and suggests potential issues with the company's asset valuation or business strategy in the Biopharma area.

Legal Proceedings

• The company is subject to a securities class action lawsuit based on allegations made in a report issued by Scorpion Capital.
• A shareholder derivative suit has also been filed against directors of the company and an employee based on similar allegations.

Related Party Transactions

• The company purchased raw materials from a related party in the amount of $1.7 million and $4.5 million for the three and nine months ended June 30, 2024, respectively.
• The company had revenues from a related party in the amount of $4.1 million and $9.7 million for the three and nine months ended June 30, 2024, respectively.

Stakeholder Impact

• Shareholders are negatively impacted by the increased net loss and impairment charges.
• Employees may be affected by the ongoing restructuring and cost-cutting measures.
• Customers may benefit from the company's continued product development and expansion.
• Creditors may be concerned about the company's increasing losses and cash burn.

Next Steps

• The company will continue to enhance its overall control environment and remediate the identified material weakness in internal control over financial reporting.
• The company will continue to invest in product development, manufacturing, and sales and marketing.
• The company will continue to monitor and manage its cash flow and liquidity.

Key Dates

Keywords

synthetic biology, DNA synthesis, genomics, NGS tools, synthetic genes, antibody discovery, biopharma, impairment, revenue growth, gross margin